Dimed S.a. Distribuidora De MedicamentosBMFBOVESPA: PNVL3

Dimed: Q2 2025 delivered robust sales, margin, and market share growth, with strong digital and expansion momentum

· Issued by Dimed S.a. Distribuidora De Medicamentos

Q2 2025 saw nearly 20% sales growth, strong EBITDA and net income gains, and continued market share expansion, driven by digital, private label, and store expansion strategies. Positive trends are expected to continue, with further margin improvements and growth in key categories.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

Earlier from Dimed S.a. Distribuidora De Medicamentos

All Dimed S.a. Distribuidora De Medicamentos news releases